<DOC>
	<DOCNO>NCT02715258</DOCNO>
	<brief_summary>The purpose study investigate effect bexagliflozin lower hemoglobin A1c ( HbA1c ) level patient type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Safety Efficacy Bexagliflozin Monotherapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Approximately 210 subject inadequately control T2DM recruit US Canada . Subjects randomly assign receive bexagliflozin tablet , 20 mg , placebo ratio 2:1 daily 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects T2DM Subjects currently take medication diabetes take one oral medication diabetes Subjects whose dos blood pressure cholesterol medication ( applicable ) change least 30 day Diagnosis type 1 diabetes mellitus maturityonset/diabetes young Current use inject therapy treatment diabetes ( insulin GLP1 receptor agonist therapy ) thiazolidinedione class drug History genitourinary tract infection Evidence abnormal liver function Myocardial infarction , stroke hospitalization heart failure within 3 month screen Prior kidney transplant evidence kidney problem Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>